• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    3/4/24 12:34:40 PM ET
    $AIMD
    $BCDA
    $BIVI
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AIMD alert in real time by email

    Gainers

    • Ocean Biomedical (NASDAQ:OCEA) shares rose 55.0% to $3.1 during Monday's regular session. The company's market cap stands at $105.6 million.
    • Jaguar Health (NASDAQ:JAGX) stock moved upwards by 54.8% to $0.14. The market value of their outstanding shares is at $6.9 million.
    • Ainos (NASDAQ:AIMD) shares increased by 39.99% to $1.47. The company's market cap stands at $6.8 million.
    • Renalytix (NASDAQ:RNLX) shares moved upwards by 36.52% to $1.42. The market value of their outstanding shares is at $70.9 million.
    • MSP Recovery (NASDAQ:LIFW) shares increased by 25.04% to $1.29. The market value of their outstanding shares is at $19.0 million.
    • Jin Medical International (NASDAQ:ZJYL) stock rose 24.68% to $7.93. The market value of their outstanding shares is at $1.2 billion.

    Losers

    • BioVie (NASDAQ:BIVI) stock decreased by 42.6% to $1.08 during Monday's regular session. The company's market cap stands at $43.2 million.
    • Vivani Medical (NASDAQ:VANI) stock fell 20.12% to $2.47. The market value of their outstanding shares is at $125.9 million.
    • First Wave BioPharma (NASDAQ:FWBI) stock declined by 19.49% to $7.44. The market value of their outstanding shares is at $11.6 million.
    • FibroBiologics (NASDAQ:FBLG) shares fell 19.24% to $10.5. The market value of their outstanding shares is at $341.1 million.
    • BioCardia (NASDAQ:BCDA) stock fell 18.89% to $0.47. The market value of their outstanding shares is at $12.1 million.
    • Benitec Biopharma (NASDAQ:BNTC) stock decreased by 17.89% to $4.62. The company's market cap stands at $11.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AIMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIMD
    $BCDA
    $BIVI
    $BNTC

    CompanyDatePrice TargetRatingAnalyst
    Benitec Biopharma Inc.
    $BNTC
    7/7/2025Buy
    TD Cowen
    Benitec Biopharma Inc.
    $BNTC
    12/16/2024$28.00Buy
    H.C. Wainwright
    Benitec Biopharma Inc.
    $BNTC
    12/13/2024$30.00Outperform
    Robert W. Baird
    FibroBiologics Inc.
    $FBLG
    12/12/2024$12.00Buy
    Rodman & Renshaw
    FibroBiologics Inc.
    $FBLG
    10/30/2024$12.00Buy
    H.C. Wainwright
    Benitec Biopharma Inc.
    $BNTC
    10/16/2024$35.00Outperform
    Oppenheimer
    FibroBiologics Inc.
    $FBLG
    9/24/2024$12.00Buy
    Maxim Group
    Benitec Biopharma Inc.
    $BNTC
    9/12/2024$17.00Buy
    Guggenheim
    More analyst ratings

    $AIMD
    $BCDA
    $BIVI
    $BNTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Khoja Hamid bought $11,400 worth of shares (30,000 units at $0.38), increasing direct ownership by 96% to 61,250 units (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/5/26 8:00:15 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER O'Heeron Pete bought $19,531 worth of shares (51,500 units at $0.38), increasing direct ownership by 0.87% to 5,958,147 units (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/4/26 5:50:10 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Davis Jason bought $28,973 worth of shares (70,000 units at $0.41) (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/3/26 8:00:20 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $BCDA
    $BIVI
    $BNTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science

    3/10/26 10:21:44 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)

    HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, is hosting an Industry Forum Breakfast and presentation on Tuesday, March 10, at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The presentation will highlight the key clinical results observed to date for OPMD Patients enrolled into the BB-301 Phase 1b/2a Clinical Treatment Study (NCT06185673) and the potential for BB-301 to transform the treatment l

    3/10/26 7:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

    - Oculopharyngeal Muscular Dystrophy (OPMD) Patients treated with low dose BB-301 and high dose BB-301 experienced significant improvements in throat closure, throat emptying, and total dysphagic symptom burden - OPMD Patients treated with low dose BB-301 experienced highly durable improvements, with clinical and radiographic improvements continuing to deepen two years post BB-301 treatment -The first OPMD Patient treated with high dose BB-301 experienced an extraordinarily robust dose-response at an early interim follow-up time-point, indicating the continued potential for BB-301 to achieve disease-modifying outcomes for OPMD patients with dysphagia - BB-301 is the only clinical-stage th

    3/9/26 7:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $BCDA
    $BIVI
    $BNTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Benitec Biopharma

    TD Cowen initiated coverage of Benitec Biopharma with a rating of Buy

    7/7/25 8:17:08 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Benitec Biopharma with a new price target

    H.C. Wainwright initiated coverage of Benitec Biopharma with a rating of Buy and set a new price target of $28.00

    12/16/24 6:46:22 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Robert W. Baird initiated coverage on Benitec Biopharma with a new price target

    Robert W. Baird initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $30.00

    12/13/24 7:25:56 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $BCDA
    $BIVI
    $BNTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Khoja Hamid bought $11,400 worth of shares (30,000 units at $0.38), increasing direct ownership by 96% to 61,250 units (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/5/26 8:00:15 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER O'Heeron Pete bought $19,531 worth of shares (51,500 units at $0.38), increasing direct ownership by 0.87% to 5,958,147 units (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/4/26 5:50:10 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Davis Jason bought $28,973 worth of shares (70,000 units at $0.41) (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/3/26 8:00:20 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $BCDA
    $BIVI
    $BNTC
    SEC Filings

    View All

    Jaguar Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - Jaguar Health, Inc. (0001585608) (Filer)

    3/9/26 9:05:16 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Jaguar Health Inc.

    8-K - Jaguar Health, Inc. (0001585608) (Filer)

    3/6/26 4:15:47 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroBiologics Inc. filed SEC Form 8-K: Leadership Update

    8-K - FibroBiologics, Inc. (0001958777) (Filer)

    3/6/26 4:03:48 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $BCDA
    $BIVI
    $BNTC
    Leadership Updates

    Live Leadership Updates

    View All

    BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

    SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the appointment of Farhan Shahab as Vice President of Quality. Mr. Shahab brings over 25 years of experience to BioCardia in similar executive roles. Mr. Shahab joins BioCardia from Welldoc (a digital health company focused on chronic disease management), where he served as Vice President of Quality and Regulatory. Prior to that, he served as Senior Director of Regulatory Affairs and Quality Assurance at Intuity Medical (a blood glucose monitoring device company), and as Dir

    11/24/25 8:15:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors

    HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Dr. Sharon Mates to the board of directors (BOD) of the Company, effective November 2, 2025. "We are delighted to welcome Dr. Sharon Mates to Benitec's Board of Directors," said Jerel Banks, M.D., Ph.D., Chairman and Chief Executive Officer of Benitec Biopharma. "Dr. Mates brings exceptional leadership experience in building successful biotechnology c

    11/3/25 7:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results

    Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115 New $10M equity financing to enable accelerated development of NPM-139 while securing financial position into the second half of 2026 Vivani to spin off Cortigent, Inc., a division of the Company that develops brain implant devices to help patients recover critical body functions, as an independent publicly traded company ALAMEDA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a biopharmaceutical company

    8/13/25 4:20:00 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AIMD
    $BCDA
    $BIVI
    $BNTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

    SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

    12/6/24 1:47:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Ainos Inc.

    SC 13D/A - Ainos, Inc. (0001014763) (Subject)

    11/27/24 6:08:44 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $BCDA
    $BIVI
    $BNTC
    Financials

    Live finance-specific insights

    View All

    BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results

    SUNNYVALE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the third quarter of 2025 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. "This quarter's $6 million financing is actively supporting approvability discussions of CardiAMP

    11/12/25 4:40:15 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025

    SUNNYVALE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2025 by conference call on Wednesday, November 12, 2025 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10204565/1005a9b26d8. Please note that registered participants will receive their dial-in number upon registration. F

    11/5/25 7:29:23 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update

    Interim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in Q4 2025 Enrollment of the First Subject into Cohort 2 of the BB-301 Phase 1b/2a Treatment Study Expected in Q4 2025 HAYWARD, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its full year ended June 30, 2025. The Company has filed its annual report on Form 10-K with the U.S. Securities and Exchange Commi

    9/22/25 4:05:00 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care